Zimbabwe has turned down a major US healthcare agreement valued at 367 million US dollars (272 million pounds) over five years because of Washington's demand for confidential biological samples.
The decision came to light after a official document dated December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "unbalanced".
An official spokesman has since clarified that the US was requesting genetic material for scientific study and profit but refused to share the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable task of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged continued dialogue to secure a deal acceptable to both sides so the country's critical HIV programme can proceed.
Wider Context
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a court suspended a similar health funding agreement following legal challenges were raised about the safety of citizens' health data.
After returning to the presidency recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump argued its spending was "inefficient" and his administration was pursuing government-to-government deals to enhance transparency and responsibility.
As per reports, 16 African countries have to date agreed to these new health pacts, representing more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation could have provided extraordinary advantages for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy through US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to provide its biological resources and data for a long time, without any equivalent guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"In essence, our nation would supply the basic resources for medical research with no certainty that the resulting innovations would be available to our population if a new pandemic arise."
National Interest and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting structures already established through the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to deal with potential global health emergencies.
"This framework is designed to ensure that when a country provides its information, the benefits – such as medicines and cures – are shared equitably, not commercialised solely by those with the capability to develop them."
The government's concerns over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage further discussions with our American counterparts on how future co-operation could be arranged in a way that honours the independence and dignity of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the government's concerns, but recommended that talks need to persist since a large portion of the nation's HIV programmes depended on external financing.
"If specific concerns arise, including those relating to data governance or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," it commented.
The halted deal underscores the complex challenges between accepting crucial international aid and safeguarding local interests in an increasingly data-driven world.